Optimizing Hematology AIM Specialty Health Integration for Prior Authorization

The Intersection of Hematology and Specialty Benefit Management

Hematology prior authorizations frequently involve high-cost specialty drugs and complex diagnostic imaging. AIM Specialty Health, operating as a specialty benefit manager for payers like Carelon (Elevance), oversees utilization for categories such as radiology, sleep, cardiology, and musculoskeletal services. For hematology, this translates to rigorous review of advanced imaging for conditions like multiple myeloma (MM/MGUS) and specific drug categories.

Key Prior Authorization Triggers in Hematology Managed by AIM

• Factor concentrates for hemophilia (e.g., Advate, Adynovate, Hemlibra, Esperoct, BeneFIX, Alprolix, Rebinyn, Idelvion), covering both prophylaxis and on-demand use.
• Sickle cell disease therapeutics (e.g., voxelotor/Oxbryta, crizanlizumab/Adakveo, gene therapies like Casgevy, Lyfgenia).
• Hematologic oncology biologics and chemotherapy, including CAR-T cell therapies (e.g., Yescarta, Kymriah, Breyanzi, Tecartus, Carvykti, Abecma) for lymphomas, leukemias, and multiple myeloma.
• Advanced specialty imaging for diagnosis and staging, particularly for MM/MGUS workups.
• Bone marrow and stem cell transplant procedures (autologous and allogeneic).

Navigating AIM Specialty Health Requirements for Hematology PAs

AIM Specialty Health's review processes demand precise clinical documentation aligned with their medical policies. For hematology, this often means adherence to specific criteria for drug initiation, dose adjustments, and imaging appropriateness. Submitting incomplete or non-compliant documentation is a primary driver of delays and denials, impacting patient access to critical care.

Essential Documentation for Hematology PAs with AIM

• Adherence to ASH guidelines for hemophilia factor concentrates, including factor level documentation, joint health status, and bleeding episode tracking.
• NCCN guidelines for hematologic oncology, detailing diagnosis confirmation, prior-line therapy documentation, and specific eligibility criteria for CAR-T cell therapies.
• Clinical notes supporting the medical necessity of specialty drugs for sickle cell disease.
• Imaging reports and clinical rationale for advanced diagnostics for MM/MGUS.
• Comprehensive patient history and treatment plan for bone marrow/stem cell transplant.

Klivira's Role in Hematology AIM Specialty Health Integration

Klivira automates the submission and tracking of prior authorizations for hematology, directly integrating with your EMR to extract necessary clinical data. Our platform incorporates ASH/NCCN-aware policy logic, hemophilia factor utilization tracking, and CAR-T eligibility documentation automation to streamline submissions to AIM Specialty Health. This reduces manual effort, accelerates approval times, and minimizes common denial reasons like NCCN-compendium gaps or hemophilia factor prophylaxis-vs-on-demand criteria.

EMR and Payer Touchpoints for Hematology Workflows

Effective hematology PA management relies on seamless data exchange. Klivira integrates via SMART on FHIR with leading EMRs to capture order types for specialty drugs and imaging. Submissions to AIM Specialty Health leverage electronic channels where available, including X12 278 transactions and ePA portals. This interoperability ensures that clinical data, such as factor levels or CAR-T eligibility, is accurately transmitted from the EMR to the specialty benefit manager, reducing friction in the authorization process.